FibroGen (FGEN) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FGEN shares.
View FGEN analyst ratings or view top-rated stocks.

6 brokerages have issued 12 month price targets for FibroGen's stock. Their FGEN share price forecasts range from $14.00 to $35.00. On average, they predict the company's share price to reach $24.83 in the next year. This suggests a possible upside of 47.8% from the stock's current price.
View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts.

FibroGen's stock was trading at $16.02 on January 1st, 2023. Since then, FGEN shares have increased by 4.9% and is now trading at $16.80.
View the best growth stocks for 2023 here.

FibroGen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 5,690,000 shares, an increase of 16.8% from the April 30th total of 4,870,000 shares. Based on an average daily volume of 910,800 shares, the days-to-cover ratio is presently 6.2 days. Approximately 6.4% of the shares of the company are short sold.
View FibroGen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our FGEN earnings forecast.

FibroGen, Inc. (NASDAQ:FGEN) released its quarterly earnings results on Monday, May, 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.05. The biopharmaceutical company had revenue of $36.16 million for the quarter, compared to the consensus estimate of $31.52 million. FibroGen had a negative trailing twelve-month return on equity of 879.75% and a negative net margin of 264.63%. FibroGen's revenue was down 40.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.68) earnings per share.

ETFs with the largest weight of FibroGen (NASDAQ:FGEN) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Small Cap Growth AlphaDEX Fund (FYC).

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.56%), State Street Corp (4.18%), First Trust Advisors LP (2.79%), Baker BROS. Advisors LP (2.70%), Armistice Capital LLC (2.37%) and Geode Capital Management LLC (1.77%). Insiders that own company stock include Christine Chung, Enrique A Conterno, Juan Graham, K Peony Yu, Kalevi Kurkijarvi, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr.
View institutional ownership trends.

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FGEN stock can currently be purchased for approximately $16.80.

FibroGen (NASDAQ:FGEN) has a market capitalization of $1.64 billion and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis.

The company employs 566 workers across the globe.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.